|99.99||0||0.00||Vol -||1Y Perf -|
|Mar 10th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||93.88||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||★★ — -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ — -|
|Insiders Value % 3/6/12 mo.||-/-/-82||Growth Ranking||★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-79||Income Ranking||— -|
|Price Range Ratio 52W %||0.00||Earnings Rating||Neutral|
|Market Cap||6.17B||Earnings Date||4th May 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-2.32|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||0|
|Avg. Monthly Volume||0|
|Avg. Quarterly Volume||0|
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) stock closed at 99.99 per share at the end of the most recent trading day (a 0.06% change compared to the prior day closing price) with a volume of 5.72M shares and market capitalization of 6.17B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 363 people. Arena Pharmaceuticals Inc. CEO is Amit D. Munshi.
The one-year performance of Arena Pharmaceuticals Inc. stock is %, while year-to-date (YTD) performance is 7.59%. ARNA stock has a five-year performance of 382.34%. Its 52-week range is between 45.5 and 100, which gives ARNA stock a 52-week price range ratio of %
Arena Pharmaceuticals Inc. currently has a PE ratio of -9.90, a price-to-book (PB) ratio of 9.16, a price-to-sale (PS) ratio of 114 173.00, a price to cashflow ratio of 4.50, a PEG ratio of 2.32, a ROA of -62.41%, a ROC of -66.69% and a ROE of -70.30%. The company’s profit margin is 47.34%, its EBITDA margin is -1 126 670.00%, and its revenue ttm is $54.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Arena Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.32 for the next earnings report. Arena Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Arena Pharmaceuticals Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Arena Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arena Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.79, ATR14 : 0.38, CCI20 : 42.00, Chaikin Money Flow : 0.34, MACD : 1.37, Money Flow Index : 0.00, ROC : 0.00, RSI : 78.90, STOCH (14,3) : 66.67, STOCH RSI : 1.00, UO : 66.99, Williams %R : -33.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arena Pharmaceuticals Inc. in the last 12-months were: Amit D. Munshi (Buy at a value of $103 325)
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.